You may already know about BRCA mutations. They’re changes or alterations that take place in your BRCA gene. Testing positive for a BRCA mutation helps determine if you can start LYNPARZA earlier in your treatment plan, after responding to the first line of platinum-based chemotherapy. If you test negative for a BRCA mutation, LYNPARZA may be an option for you later in your treatment plan. Ask to be tested as early as diagnosis.
This type of mutation is passed down from a family member. It can be found in your blood, saliva, or tumor.
*There is an FDA-approved test that detects inherited BRCA mutations to determine if you are able to take LYNPARZA as a maintenance treatment after responding to the first line of platinum-based chemotherapy.
This type of mutation is not passed down—it occurs randomly. It can only be found in your tumor. Blood or saliva testing cannot find acquired BRCA mutations.
†Currently, there is not an FDA-approved test that detects acquired BRCA mutations to determine if you are able to take LYNPARZA as a maintenance treatment after responding to the first line of platinum-based chemotherapy.
If you have either of these mutations, you may be able to start LYNPARZA earlier.
Be your own advocate and talk to your health care provider today about testing early for a BRCA mutation.
You’ll notice that you need to have a BRCA mutation in order to be prescribed LYNPARZA after responding to the first line of platinum-based chemotherapy, whereas after responding to the second line of platinum-based chemotherapy, you may be prescribed LYNPARZA regardless of whether or not you have a BRCA mutation.
LYNPARZA was studied in women like you—both with and without a BRCA mutation.
Ask your health care provider when you’ll be tested for a BRCA mutation. You could be tested as early as diagnosis.
LYNPARZA is a prescription medicine used to treat adults who have:
It is not known if LYNPARZA is safe and effective in children.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:
Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?
What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects. The most common side effects of LYNPARZA are:
These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.
You may report side effects related to AstraZeneca products by clicking here.
Please click here for complete Prescribing Information, including Patient Information (Medication Guide).